RCC-36 hydrochloride 

RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K⁺ currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity^[1][2][3].

RCC-36 (10 μM；5 分钟) hydrochloride 可在体外以电压和浓度依赖的方式抑制分离的豚鼠逼尿肌平滑肌细胞中的 L 型钙电流；在-60 mV 的钳制电位下其 IC₅₀ 为 6.4 µM，在-40 mV 的钳制电位下为 1.2 µM，并且可通过使稳态失活曲线超极化移位 (不改变激活曲线) 来降低钙窗电流^[1]。
RCC-36 (1-100 µM) hydrochloride 可强效抑制分离的豚鼠心室肌细胞中的 L 型 Ca²⁺电流，其 IC₅₀ 为 27.0 µM^[2]。
RCC-36 (10 nM-3 μM；至少 30 分钟) hydrochloride 在离体人逼尿肌平滑肌上表现出竞争性抗胆碱能活性，其 pA₂ 值为 7.20，并在 3 μM 浓度下抑制乙酰胆碱诱导的最大收缩^[3]。
RCC-36 (1 μM-1 mM；至少 30 分钟) hydrochloride 可抑制 80 mM KCl 诱导的离体人逼尿肌平滑肌收缩，最大抑制率为 87.1%，IC₅₀ 为 13.0 μM^[3]。
RCC-36 (100 nM-1 mM；至少 30 分钟) hydrochloride 可强效抑制 5 mM CaCl₂ 诱导的人离体逼尿肌平滑肌收缩，最大抑制率达 98.5%，IC₅₀ 为 1.34 μM^[3]。
RCC-36 (1 nM-200 μM；至少 30 分钟) hydrochloride 可抑制电场诱导的离体人逼尿肌平滑肌收缩，最大抑制率为 81.1%，IC₅₀ 为 2653 μM^[3]。
RCC-36 (10 nM-300 μM；至少 30 分钟) hydrochloride 可强效抑制离体人逼尿肌平滑肌中 Atropine (HY-B1205) 抵抗性电场诱导的收缩，最大抑制率达 82.3%，IC₅₀ 为 2.65 μM^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

393.95

C₂₂H₃₂ClNO₃

129927-37-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hayashi S, et al. Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol. 1997;355(5):659-666.  [Content Brief]

  [2]. Hayashi S, et al. Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline. Naunyn Schmiedebergs Arch Pharmacol. 1997;355(5):651-658.  [Content Brief]

  [3]. Kikukawa H, et al. Pharmacologic actions of temiverine (p-INN) and its active metabolite, RCC-36, on isolated human urinary bladder muscle. Int J Urol. 1998;5(3):268-275.  [Content Brief]